Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha

Author(s): Xiaoming Lu, Chao Cheng, Guobin Wang, Xiaogang Shu, Jingwei Ma, Qiang Tong.

Journal Name: Protein & Peptide Letters

Volume 20 , Issue 4 , 2013

Become EABM
Become Reviewer


The fusion protein MG7-scFv/SEB has shown anti-tumor activity on gastric cancer in vitro and in vivo. Tumor necrosis factor-alpha (TNF-α) is a cytokine exerting anti-tumor effectiveness in various models and modes of applications. In this study, we explored the combination effects of MG7-scFv/SEB and TNF-α in experimental gastric cancer. Both MG7-scFv/SEB and TNF-α could effectively result in a significant inhibition of tumor growth in our experimental models when administered alone. What’s more, MG7-scFv/SEB synergized with TNF-α in further reducing the growth of gastric tumors in gastric-tumor-bearing rats as compared to mono therapy. Additionally, the survival rate of gastric-tumorbearing rats administrated with combined therapy was significantly higher than that of rats treated with MG7-scFv/SEB or TNF-α. These results indicate that combined therapy with MG7-scFv/SEB and TNF-α is a promising strategy for human cancer therapy.

Keywords: Superantigens, MG7-scFv/SEB, tumor necrosis factor, combination, gastric cancer, fusion protein, cytokine, gastric tumor, combined therapy, cancer therapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [467 - 472]
Pages: 6
DOI: 10.2174/0929866511320040011
Price: $65

Article Metrics

PDF: 9